INVESTIGATIONAL PIPELINE A POWERFUL RESEARCH AND DEVELOPMENT ENGINE
Explore Regeneron's clinical pipeline
Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, the Global Development team brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron. This page is intended for U.S. residents only.
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.
Download Our Corporate Fact SheetDisplaying item
Molecule Name
Therapeutic Area
Modality
Indication
Target
-
27T51
Therapeutic Area
Oncology
Modality
Cell therapy
Indication
Ovarian cancer
Target
MUC16
-
ALN-ANG3
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Gene silencing
Indication
Healthy volunteers
Target
ANGPTL3
-
ALN-HTT02 In collaboration with Alnylam
Therapeutic Area
Neurology
Modality
Gene silencing
Indication
Huntington’s disease
Target
HTT
-
ALN-PNP In collaboration with Alnylam
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Gene silencing
Indication
Non-Alcoholic Fatty Liver Disease (NAFLD)
Target
PNPLA3
-
ALN-SOD*
In collaboration with Alnylam*on U.S. FDA clinical hold;
enrolling ex–U.S.Therapeutic Area
Neurology
Modality
Gene silencing
Indication
SOD1 amyotrophic lateral sclerosis (ALS)
Target
SOD1
-
DB-OTO
Therapeutic Area
Rare Disease
Modality
Gene therapy
Indication
Hearing loss in pediatrics (Phase 1/2)
Target
AAV-based gene therapy
-
DUPILUMAB/ LINVOSELTAMAB
Therapeutic Area
Immunology & Inflammation
Modality
Bispecific antibodies
Monoclonal antibodies
Indication
Severe food allergy
Target
IL-4R/BCMA and CD3
-
FIANLIMAB
Therapeutic Area
Oncology
Hematology
Modality
Monoclonal antibodies
Indication
Solid tumors and advanced hematologic malignancies
Target
LAG-3
-
LINVOSELTAMAB
Therapeutic Area
Hematology
Modality
Bispecific antibodies
Indication
Multiple myeloma
Target
BCMA and CD3
-
"NEXT GENERATION" COVID ANTIBODY
Therapeutic Area
Infectious Disease
Modality
Monoclonal antibodies
Indication
Healthy volunteers
Target
SARS-CoV-2 variants
-
Nezastomig (REGN5678)
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Renal cell carcinoma
Target
PSMA and CD28
-
Nezastomig (REGN5678) / REGN4336
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Prostate cancer
Target
PSMA and CD28 / PSMA and CD3 combo
-
Nexiguran ziclumeran (NTLA-2001) In collaboration with Intellia
Therapeutic Area
Rare Disease
Neurology
Modality
Gene editing
Indication
Transthyretin amyloidosis with Polyneuropathy (ATTR-PN)
Target
TTR gene knockout using CRISPR/Cas9
-
ODRONEXTAMAB
Therapeutic Area
Oncology
Hematology
Modality
Bispecific antibodies
Indication
Certain B-cell malignancies
Target
CD20 and CD3
-
REGN10597
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Solid tumors (Phase 1/2)
Target
PD1-IL2Ra
-
REGN13335
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Monoclonal antibodies
Indication
Healthy volunteers
Target
PDGF-b antagonist
-
REGN4336
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Prostate cancer
Target
PSMA and CD3
-
REGN5093-M114
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
MET overexpressing advanced cancer
Target
Two distinct MET epitopes
-
REGN9035
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Monoclonal antibodies
Indication
Reversal agent to REGN5381 in healthy volunteers
Target
NPR1
-
REGV131-LNP1265
Therapeutic Area
Hematology
Modality
Gene editing
Indication
Hemophilia B
Target
Factor 9
-
Vonsetamig (REGN5459)
Therapeutic Area
Oncology
Hematology
Modality
Bispecific antibodies
Indication
Transplant desensitization in patients with chronic kidney disease
Target
BCMA and CD3
-
REGN5668
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Platinum-resistant ovarian cancer
Target
MUC16 and CD28
-
REGN5837
Therapeutic Area
Hematology
Modality
Bispecific antibodies
Indication
B-NHL
Target
CD22 and CD28
-
REGN7544
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Monoclonal antibodies
Indication
Healthy volunteers
Target
NPR1 antagonist
Molecule Name
Therapeutic Area
Modality
Indication
Target
-
Davutamig (REGN5093)
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
MET-altered advanced NSCLC
Target
Two distinct MET epitopes
-
Rapirosiran (ALN-HSD)
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Gene silencing
Indication
Metabolic dysfunction-associated steatohepatitis (MASH)
Target
HSD17B13
-
CEMIPLIMAB
Therapeutic Area
Oncology
Modality
Monoclonal antibodies
Indication
Neoadjuvant cutaneous squamous cell carcinoma (CSCC); First-line non-small cell lung cancer (NSCLC), BNT116 combination; Neoadjuvant NSCLC; Neoadjuvant hepatocellular carcinoma (HCC)
Target
PD-1
-
DUPILUMAB In collaboration with Sanofi
Therapeutic Area
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Ulcerative colitis; Eosinophilic gastroenteritis (Phase 2/3)
Target
IL-4R alpha subunit
-
FIANLIMAB
Therapeutic Area
Oncology
Modality
Monoclonal antibodies
Indication
First-line advanced non-small cell lung cancer (NSCLC) (Phase 2/3); Perioperative NSCLC; Perioperative melanoma (Phase 2/3)
Target
LAG-3
-
ITEPEKIMAB In collaboration with Sanofi
Therapeutic Area
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Non-cystic fibrosis bronchiectasis (NCFB)
Target
IL-33
-
LINVOSELTAMAB
Therapeutic Area
Oncology
Hematology
Modality
Bispecific antibodies
Indication
Multiple myeloma (pivotal study); Earlier (pre-malignant) multiple myeloma; Monoclonal gammopathy of undetermined significance (MGUS); Light chain amyloidosis (ALA)
Target
BCMA and CD3
-
MIBAVADEMAB
Therapeutic Area
Cardiovascular/ Metabolic
Rare Disease
Modality
Monoclonal antibodies
Indication
Generalized lipodystrophy
Target
Leptin receptor (LEPR)
-
Nezastomig (REGN5678)
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Prostate cancer
Target
PSMA and CD28
-
ODRONEXTAMAB
Therapeutic Area
Cardiovascular/ Metabolic
Oncology
Hematology
Modality
Bispecific antibodies
Indication
B-cell non-Hodgkin lymphoma (B-NHL) (pivotal study)
Target
CD20 and CD3
-
REGN5381
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Monoclonal antibodies
Indication
Heart failure
Target
NPR1
-
REGN7075
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Solid tumors
Target
EGFR and CD28
-
REGN7257
Therapeutic Area
Hematology
Modality
Monoclonal antibodies
Indication
Aplastic anemia
Target
IL2Rg
-
REGN7508
Therapeutic Area
Hematology
Modality
Monoclonal antibodies
Indication
Thrombosis
Target
Factor XI
-
REGN7999
Therapeutic Area
Hematology
Modality
Monoclonal antibodies
Indication
Iron overload in beta-thalassemia
Target
TMPRSS6
-
REGN9933
Therapeutic Area
Hematology
Modality
Monoclonal antibodies
Indication
Thrombosis
Target
Factor XI
-
SARILUMAB In collaboration with Sanofi
Therapeutic Area
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Systemic juvenile idiopathic arthritis (sJIA) (pivotal study)
Target
IL-6R
-
Trevogrumab (REGN1033)
Therapeutic Area
Cardiovascular/ Metabolic
Modality
Monoclonal antibodies
Indication
Obesity
Target
Myostatin (GDF8)
-
UBAMATAMAB (REGN4018)
Therapeutic Area
Oncology
Modality
Bispecific antibodies
Indication
Platinum-resistant ovarian cancer
Target
MUC16 and CD3
Molecule Name
Therapeutic Area
Modality
Indication
Target
-
CEMIPLIMAB
Therapeutic Area
Oncology
Modality
Monoclonal antibodies
Indication
Adjuvant cutaneous squamous cell carcinoma (CSCC)
Target
PD-1
-
DUPILUMAB In collaboration with Sanofi
Therapeutic Area
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Asthma in pediatrics (2–5 years of age); bullous pemphigoid; chronic spontaneous urticaria (CSU); chronic pruritis of unknown origin (CPUO)
Target
IL-4R alpha subunit
-
EYLEA HD (aflibercept) 8 mg In collaboration with Bayer
Therapeutic Area
Ophthalmology
Modality
Traps
Indication
Retinal vein occlusion (RVO)
Target
VEGF
-
FIANLIMAB
Therapeutic Area
Oncology
Modality
Monoclonal antibodies
Indication
First-line metastatic melanoma; Adjuvant melanoma; First-line metastatic melanoma versus the combination of relatlimab and nivolumab
Target
LAG-3
-
GARETOSMAB
Therapeutic Area
Rare Disease
Modality
Monoclonal antibodies
Indication
Fibrodysplasia ossificans progressiva (FOP)
Target
Activin A
-
ITEPEKIMAB In collaboration with Sanofi
Therapeutic Area
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Chronic obstructive pulmonary disease (COPD)
Target
IL-33
-
LINVOSELTAMAB
Therapeutic Area
Hematology
Modality
Bispecific antibodies
Indication
Multiple myeloma
Target
BCMA and CD3
-
Nexiguran ziclumeran (NTLA-2001) In collaboration with Intellia
Therapeutic Area
Cardiovascular/ Metabolic
Rare Disease
Hematology
Modality
Gene editing
Indication
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
Target
TTR gene knockout using CRISPR/Cas9
-
ODRONEXTAMAB
Therapeutic Area
Hematology
Modality
Bispecific antibodies
Indication
Follicular lymphoma (FL); Diffuse large B-cell lymphoma (DLBCL)
Target
CD20 and CD3
-
POZELIMAB (REGN3918)
Therapeutic Area
Ophthalmology
Neurology
Hematology
Modality
Monoclonal antibodies
Gene silencing
Indication
Myasthenia gravis, cemdisiran combination; paroxysmal nocturnal hemoglobinuria (PNH), cemdisiran combination; Geographic atrophy, cemdisiran combination
Target
C5
-
REGN5713-5714-5715
Therapeutic Area
Immunology & Inflammation
Modality
Monoclonal antibodies
Indication
Birch allergy
Target
Bet v 1
No results found. Please adjust your filter selection and try again.
Technology for now
and the future
Technology is foundational to our work inventing new medicines. By combining the deep scientific expertise of our team with our proprietary VelociSuite® technologies, as well as other complementary technologies, we accelerate the way medicines are traditionally discovered and developed.
Explore Our Technology
Explore our clinical trials
The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.
Find Trials